Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

Original languageEnglish
Pages (from-to)1837-1841
Number of pages5
JournalLeukemia Research
Volume32
Issue number12
DOIs
Publication statusPublished - 12-2008
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this